| Literature DB >> 28749475 |
Sumit Parikh1, Amy Goldstein2, Amel Karaa3, Mary Kay Koenig4, Irina Anselm5, Catherine Brunel-Guitton6, John Christodoulou7, Bruce H Cohen8, David Dimmock9, Gregory M Enns10, Marni J Falk11, Annette Feigenbaum12,13, Richard E Frye14, Jaya Ganesh15, David Griesemer16, Richard Haas17,18, Rita Horvath19, Mark Korson20, Michael C Kruer21, Michelangelo Mancuso22, Shana McCormack23, Marie Josee Raboisson24, Tyler Reimschisel25, Ramona Salvarinova26, Russell P Saneto27, Fernando Scaglia28, John Shoffner29, Peter W Stacpoole30, Carolyn M Sue31, Mark Tarnopolsky32, Clara Van Karnebeek33,34, Lynne A Wolfe35, Zarazuela Zolkipli Cunningham36, Shamima Rahman37, Patrick F Chinnery38.
Abstract
The purpose of this statement is to provide consensus-based recommendations for optimal management and care for patients with primary mitochondrial disease. This statement is intended for physicians who are engaged in the diagnosis and management of these patients. Working group members were appointed by the Mitochondrial Medicine Society. The panel included members with several different areas of expertise. The panel members utilized surveys and the Delphi method to reach consensus. We anticipate that this statement will need to be updated as the field continues to evolve. Consensus-based recommendations are provided for the routine care and management of patients with primary genetic mitochondrial disease.Entities:
Mesh：
Year: 2017 PMID： 28749475 PMCID： PMC7804217 DOI： 10.1038/gim.2017.107
Source DB: PubMed Journal: Genet Med ISSN： 1098-3600 Impact factor: 8.822